Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
BLTE | US
2.28
4.68%
Healthcare
Biotechnology
30/06/2024
04/10/2024
50.99
50.98
51.15
50.49
Belite Bio Inc a clinical stage biopharmaceutical drug development company engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases (STGD1). Its lead product candidate is LBS-008 (Tinlarebant) an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in STGD1 and GA patients. The company is also developing LBS-009 an anti-retinol binding protein 4 oral therapy targeting liver disease including non-alcoholic fatty liver disease nonalcoholic steatohepatitis type 2 diabetes and gout which is in the preclinical development phase. Belite Bio Inc was founded in 2016 and is based in San Diego California. Belite Bio Inc operates as a subsidiary of Lin Bioscience International Ltd.
View LessPositive Momentum
Strength based on increasing price with high volume
Strong Sharpe Ratio (> 1.2)
High Short-term Volatility
Smallcap (300M - 2B USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Rich in Valuation (Price to Book > 8)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
32.7%1 month
23.1%3 months
28.7%6 months
36.1%-
-
12.44
-
-
-35.61
-
-
-36.54M
1.56B
1.56B
-
-
-
-
-41.44
10.87
2.21
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
7.45
Range1M
7.45
Range3M
7.45
Rel. volume
1.51
Price X volume
2.56M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Arvinas Inc | ARVN | Biotechnology | 24.96 | 1.71B | 1.05% | n/a | 0.38% |
PROK | PROK | Biotechnology | 1.695 | 1.65B | 3.04% | n/a | -0.69% |
NewAmsterdam Pharma Company N.V. Ordinary Shares | NAMS | Biotechnology | 18.22 | 1.64B | 4.53% | n/a | 0.15% |
Bicycle Therapeutics Limited | BCYC | Biotechnology | 23.6 | 1.63B | 4.61% | n/a | 4.89% |
Ardelyx Inc | ARDX | Biotechnology | 6.82 | 1.61B | -1.59% | n/a | 71.36% |
Syndax Pharmaceuticals Inc | SNDX | Biotechnology | 18.82 | 1.60B | -3.19% | n/a | 0.26% |
BioCryst Pharmaceuticals Inc | BCRX | Biotechnology | 7.58 | 1.57B | 2.71% | n/a | -178.85% |
Immunocore Holdings plc | IMCR | Biotechnology | 31.11 | 1.56B | 0.06% | n/a | 131.69% |
Ocular Therapeutix Inc | OCUL | Biotechnology | 9.84 | 1.53B | 5.69% | n/a | 19.83% |
Arcus Biosciences Inc | RCUS | Biotechnology | 16.65 | 1.52B | 8.19% | n/a | 1.73% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -35.61 | 0.76 | Cheaper |
Ent. to Revenue | - | 3,674.48 | - |
PE Ratio | - | 38.01 | - |
Price to Book | 12.44 | 14.10 | Par |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 28.70 | 74.67 | Lower Risk |
Debt to Equity | - | -1.82 | - |
Debt to Assets | - | 0.26 | - |
Market Cap | 1.56B | 3.73B | Emerging |